Abstract
In recent years, our knowledge regarding the metabolism of melanoma has greatly advanced and consequently new therapeutic strategies are being developed. This review is focused on metabolic pathways contributing to melanoma proliferation, the influence of BRAF inhibitors on those metabolic pathways and finally a presentation of potential therapeutic strategies aimed at blocking metabolic signaling pathways and therefore melanoma development.
Keywords: Glycolysis, mitochondria, oxidative stress, warburg.
Current Cancer Drug Targets
Title:Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Volume: 14 Issue: 4
Author(s): Philippe Marchetti, Pierre Guerreschi, Jerome Kluza and Laurent Mortier
Affiliation:
Keywords: Glycolysis, mitochondria, oxidative stress, warburg.
Abstract: In recent years, our knowledge regarding the metabolism of melanoma has greatly advanced and consequently new therapeutic strategies are being developed. This review is focused on metabolic pathways contributing to melanoma proliferation, the influence of BRAF inhibitors on those metabolic pathways and finally a presentation of potential therapeutic strategies aimed at blocking metabolic signaling pathways and therefore melanoma development.
Export Options
About this article
Cite this article as:
Marchetti Philippe, Guerreschi Pierre, Kluza Jerome and Mortier Laurent, Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?, Current Cancer Drug Targets 2014; 14 (4) . https://dx.doi.org/10.2174/1568009614666140407113124
DOI https://dx.doi.org/10.2174/1568009614666140407113124 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Conceptualizing the Multifaceted Determinants of the Duration of Untreated Psychosis
Current Psychiatry Reviews Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma
Anti-Cancer Agents in Medicinal Chemistry HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Glycosyltransferase and Glypiation Inhibitors
Current Organic Chemistry 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Stimuli-responsive Smart Liposomes in Cancer Targeting
Current Drug Targets Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Is Senescence Reversible?
Current Drug Targets Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells
Anti-Cancer Agents in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets